Key Points Angiogenesis and VEGF have important roles in the pathogenesis of breast cancer VEGF is regulated by complex factors including hypoxia, growth factors, hormones and activated oncogenes Angiogenic markers, such as VEGF, can be of prognostic and predictive value in breast cancer Clinical trials of antiangiogenic agents such as bevacizumab and tyrosine kinase inhibitors in breast cancer are ongoing Bevacizumab in combination with paclitaxel can improve progression-free survival in patients with previously untreated metastatic breast cancer Challenges facing the success of antiangiogenic therapy in breast cancer include the identification of biomarkers to guide management, overcoming drug resistance and identifying the correct target population This is a preview of subscription content, access via your institution Access options Subscribe to this journal Receive 12 print issues and online access 183,71 per year only 15,31 per issue Buy this article Purchase on SpringerLink Instant access to the full article PDF
pyogenes (4 g/ml)
Bladder cancer has become the most common malignancy of the urinary system, and there is currently no effective treatment strategy for invasive bladder cancer
Ipamorelin vs CJC-1295 Ipamorelin and CJC-1295 are not interchangeable they work on different receptors
In the detection medium containing 32% ethanol, the adduct is poorly soluble and forms aggregates, thus switching on the fluorescence
We improved medial collateral ligament (mcl) healing throughout 90 days after surgical transection
